Overview

Camrelizumab Plus Doxorubicin for the First Line Treatment of Adcanced Soft Tissue Sarcoma

Status:
Recruiting
Trial end date:
2023-11-12
Target enrollment:
Participant gender:
Summary
To evaluate the efficacy and safety of the combination of adriamycin and Camrelizumab in the first-line treatment of advanced soft tissue sarcoma
Phase:
Phase 2
Details
Lead Sponsor:
Wuhan Union Hospital, China
Treatments:
Doxorubicin
Liposomal doxorubicin